Form 4: Rapid Micro Biosystems Director Richard Kollender Receives Significant Equity Compensation

Rapid Micro Biosystems, Inc. Director Richard S. Kollender was granted 14,300 restricted stock units and 28,650 stock options as part of his compensation, as reported in a recent SEC Form 4 filing.

Summary

• Richard S. Kollender, a Director of Rapid Micro Biosystems, Inc. (RPID), reported the acquisition of equity securities on May 22, 2025.
• Mr. Kollender was granted 14,300 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs are set to vest in full on the earlier of the first anniversary of the grant date (May 22, 2026) or the day immediately prior to the next annual meeting of stockholders, contingent on continuous service.
• Additionally, Mr. Kollender received a grant of 28,650 stock options with an exercise price of $3.15 per share.
• These stock options also vest in full on the earlier of the first anniversary of the grant date (May 22, 2026) or the day immediately prior to the next annual meeting of stockholders, contingent on continuous service, and are set to expire on May 21, 2035.
• Following these transactions, Mr. Kollender beneficially owns 111,018 shares of Class A Common Stock and 28,650 stock options directly.

Sentiment

Score: 7

Explanation: The filing indicates standard equity compensation for a director, which is a positive for aligning interests and retaining talent, but does not reflect new operational or financial performance that would significantly alter the company's outlook.

Positives

• The grant of equity compensation, including RSUs and stock options, aligns the director's financial interests directly with the long-term performance and shareholder value of Rapid Micro Biosystems.
• The acquisition of 14,300 restricted stock units at a $0 price provides the director with direct equity ownership, incentivizing commitment.
• The grant of 28,650 stock options offers potential upside for the director, contingent on the company's stock price appreciating above the $3.15 exercise price.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon the reporting person remaining in continuous service with the company until the specified vesting date, meaning forfeiture if service ceases prematurely.
• The ultimate value realized from the stock options is dependent on the future market price of Rapid Micro Biosystems' Class A Common Stock exceeding the exercise price of $3.15 per share.

Future Outlook

The vesting schedule for the granted RSUs and stock options ties the director's equity compensation to continued service for at least one year or until the next annual meeting, aligning future incentives with the company's long-term performance and strategic goals.

Industry Context

This Form 4 filing reflects a common and standard practice within publicly traded companies, particularly in the biotechnology and life sciences sectors, where equity compensation is a primary tool for attracting, retaining, and incentivizing directors and key executives. It does not provide broader industry trends beyond this compensation practice.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options for director compensation is a widely adopted practice across publicly traded companies, consistent with global benchmarks for executive and board remuneration.
• The vesting period, typically one year or until the next annual meeting, is standard for such grants, designed to ensure continued commitment and alignment of interests.
• The exercise price of $3.15 for the options would typically be compared to the company's stock price on the grant date to assess if they were granted at-the-money, in-the-money, or out-of-the-money, which is a common variable in equity compensation plans across comparable companies.

Stakeholder Impact

• Shareholders: The grant of equity compensation aligns the director's interests with shareholders, potentially leading to better long-term performance. The issuance of shares upon vesting/exercise will result in minor dilution.
• Employees: This specific filing primarily concerns director compensation and does not directly impact the broader employee base.

Next Steps

• The Restricted Stock Units and stock options are expected to vest on the earlier of May 22, 2026 (the first anniversary of the grant date) or the day immediately prior to the next annual meeting of stockholders, provided continuous service.
• The stock options will expire on May 21, 2035, if not exercised by that date.

Key Dates

Keywords

Rapid Micro Biosystems, RPID, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Beneficial Ownership